Stan Berenshteyn
Stock Analyst at Wells Fargo
(1.02)
# 3,835
Out of 5,182 analysts
86
Total ratings
33.33%
Success rate
-19.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stan Berenshteyn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHR Phreesia | Maintains: Overweight | $30 → $25 | $8.60 | +190.70% | 2 | Mar 26, 2026 | |
| CTEV Claritev | Maintains: Equal-Weight | $30 → $22 | $18.14 | +21.28% | 3 | Mar 19, 2026 | |
| HCAT Health Catalyst | Downgrades: Equal-Weight | $5 → $1 | $1.12 | -10.71% | 8 | Mar 18, 2026 | |
| VEEV Veeva Systems | Maintains: Overweight | $333 → $317 | $159.09 | +99.26% | 10 | Mar 5, 2026 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $7 → $3.5 | $2.23 | +56.95% | 9 | Mar 4, 2026 | |
| TDOC Teladoc Health | Maintains: Equal-Weight | $8 → $6 | $5.24 | +14.50% | 4 | Feb 26, 2026 | |
| WAY Waystar Holding | Maintains: Overweight | $41 → $36 | $22.43 | +60.50% | 2 | Feb 19, 2026 | |
| DOCS Doximity | Maintains: Overweight | $55 → $45 | $22.25 | +102.25% | 14 | Feb 6, 2026 | |
| HNGE Hinge Health | Initiates: Overweight | $68 | $38.78 | +75.35% | 1 | Jan 9, 2026 | |
| OMDA Omada Health | Initiates: Equal-Weight | $17 | $12.46 | +36.44% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $52 | $36.33 | +43.13% | 18 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $5.51 | +63.34% | 5 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $125 | $81.36 | +53.64% | 9 | Feb 26, 2025 |
Phreesia
Mar 26, 2026
Maintains: Overweight
Price Target: $30 → $25
Current: $8.60
Upside: +190.70%
Claritev
Mar 19, 2026
Maintains: Equal-Weight
Price Target: $30 → $22
Current: $18.14
Upside: +21.28%
Health Catalyst
Mar 18, 2026
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $1.12
Upside: -10.71%
Veeva Systems
Mar 5, 2026
Maintains: Overweight
Price Target: $333 → $317
Current: $159.09
Upside: +99.26%
GoodRx Holdings
Mar 4, 2026
Maintains: Overweight
Price Target: $7 → $3.5
Current: $2.23
Upside: +56.95%
Teladoc Health
Feb 26, 2026
Maintains: Equal-Weight
Price Target: $8 → $6
Current: $5.24
Upside: +14.50%
Waystar Holding
Feb 19, 2026
Maintains: Overweight
Price Target: $41 → $36
Current: $22.43
Upside: +60.50%
Doximity
Feb 6, 2026
Maintains: Overweight
Price Target: $55 → $45
Current: $22.25
Upside: +102.25%
Hinge Health
Jan 9, 2026
Initiates: Overweight
Price Target: $68
Current: $38.78
Upside: +75.35%
Omada Health
Jan 9, 2026
Initiates: Equal-Weight
Price Target: $17
Current: $12.46
Upside: +36.44%
Jan 5, 2026
Maintains: Overweight
Price Target: $43 → $52
Current: $36.33
Upside: +43.13%
Nov 5, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $5.51
Upside: +63.34%
Feb 26, 2025
Maintains: Overweight
Price Target: $110 → $125
Current: $81.36
Upside: +53.64%